sun pharma shares

Pharma major Sun Pharma is expected to report healthy revenue growth during the second quarter, driven by its domestic business, which benefits from favorable seasonality and growing volumes. Revenue from operations is likely to jump 10% year-on-year (YoY), according to the average estimate of four brokerages. Meanwhile, net profit for the quarter is projected to…